1. Home
  2. LRMR vs AKBA Comparison

LRMR vs AKBA Comparison

Compare LRMR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$3.03

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.47

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LRMR
AKBA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.5M
248.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
LRMR
AKBA
Price
$3.03
$0.47
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
★ $14.40
$3.00
AVG Volume (30 Days)
1.3M
★ 8.9M
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.36
52 Week High
$6.42
$1.84

Technical Indicators

Market Signals
Indicator
LRMR
AKBA
Relative Strength Index (RSI) 59.82 36.35
Support Level $2.89 $0.36
Resistance Level $4.19 $1.54
Average True Range (ATR) 0.25 0.07
MACD 0.09 -0.01
Stochastic Oscillator 95.93 24.73

Price Performance

Historical Comparison
LRMR
AKBA

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: